Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined w...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2021-10-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0271.htm |
| _version_ | 1819261493219164160 |
|---|---|
| author | YU Xuxu LI Xiangke YANG Minjie CHEN Zhong MAO Yinggang SONG Lijie |
| author_facet | YU Xuxu LI Xiangke YANG Minjie CHEN Zhong MAO Yinggang SONG Lijie |
| author_sort | YU Xuxu |
| collection | DOAJ |
| description | Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined with anlotinib from the First Affiliated Hospital of Zhengzhou University. Results A total of 45 patients, including 24 males and 21 females, were included. The median age was 57 years old. The primary tumor sites were lung (23 cases, 51.1%), esophagus (8 cases, 17.8%), pancreas (7 cases, 15.6%) and rectum (7 cases, 15.6%). Eighteen cases (40%) had failed the first- and second-line treatments, and 27 cases (60%) had failed the third-line and above treatments. All patients received 2-15 cycles of treatment, 3 cases died due to disease progression, overall objective response rate was 11.1%, disease control rate was 53.5%, median progression-free survival was 5.8 months, and 10-month progression-free survival rate was 25.5%. Adverse events were mainly grade 1-2 myelosuppression and digestive tract reactions. Conclusion PD-1 combined with anlotinib show better efficacy and good tolerance on advanced neuroendocrine carcinoma. It can be used as a choice after the failure of standard first-line treatment of advanced neuroendocrine carcinoma. |
| first_indexed | 2024-12-23T19:42:40Z |
| format | Article |
| id | doaj.art-186b970ee9bb445ab2de5a5302123faf |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-12-23T19:42:40Z |
| publishDate | 2021-10-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-186b970ee9bb445ab2de5a5302123faf2022-12-21T17:33:36ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782021-10-01481097497810.3971/j.issn.1000-8578.2021.21.02718578.2021.21.0271Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine CarcinomaYU Xuxu0LI Xiangke1YANG Minjie2CHEN Zhong3MAO Yinggang4SONG Lijie5Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, ChinaObjective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined with anlotinib from the First Affiliated Hospital of Zhengzhou University. Results A total of 45 patients, including 24 males and 21 females, were included. The median age was 57 years old. The primary tumor sites were lung (23 cases, 51.1%), esophagus (8 cases, 17.8%), pancreas (7 cases, 15.6%) and rectum (7 cases, 15.6%). Eighteen cases (40%) had failed the first- and second-line treatments, and 27 cases (60%) had failed the third-line and above treatments. All patients received 2-15 cycles of treatment, 3 cases died due to disease progression, overall objective response rate was 11.1%, disease control rate was 53.5%, median progression-free survival was 5.8 months, and 10-month progression-free survival rate was 25.5%. Adverse events were mainly grade 1-2 myelosuppression and digestive tract reactions. Conclusion PD-1 combined with anlotinib show better efficacy and good tolerance on advanced neuroendocrine carcinoma. It can be used as a choice after the failure of standard first-line treatment of advanced neuroendocrine carcinoma.http://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0271.htmimmune checkpoint inhibitorpd-1anlotinibneuroendocrine carcinoma |
| spellingShingle | YU Xuxu LI Xiangke YANG Minjie CHEN Zhong MAO Yinggang SONG Lijie Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma Zhongliu Fangzhi Yanjiu immune checkpoint inhibitor pd-1 anlotinib neuroendocrine carcinoma |
| title | Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma |
| title_full | Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma |
| title_fullStr | Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma |
| title_full_unstemmed | Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma |
| title_short | Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma |
| title_sort | efficacy and safety of pd 1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma |
| topic | immune checkpoint inhibitor pd-1 anlotinib neuroendocrine carcinoma |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0271.htm |
| work_keys_str_mv | AT yuxuxu efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT lixiangke efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT yangminjie efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT chenzhong efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT maoyinggang efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT songlijie efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma |